Neimeth International Pharmaceuticals Plc

NGSE:NEIMETH Stock Report

Mkt Cap: ₦3.0b

We’ve recently updated our valuation analysis.

Neimeth International Pharmaceuticals Valuation

Is NEIMETH undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for NEIMETH?

Other financial metrics that can be useful for relative valuation.

NEIMETH key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue2.3x
Enterprise Value/EBITDA171.1x
PEG Ration/a

Price to Sales Ratio vs Peers

How does NEIMETH's PS Ratio compare to its peers?

The above table shows the PS ratio for NEIMETH vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPSEstimated GrowthMarket Cap
Peer Average4.9x
GLAXOSMITH GlaxoSmithKline Consumer Nigeria
0.3xn/a₦7.8b
MAYBAKER May & Baker Nigeria
0.6xn/a₦8.4b
FIDSON Fidson Healthcare
0.6xn/a₦22.7b
VIV Avivagen
18.2x129.7%CA$7.3m
NEIMETH Neimeth International Pharmaceuticals
1xn/a₦3.0b

Price-To-Sales vs Peers: NEIMETH is good value based on its Price-To-Sales Ratio (1x) compared to the peer average (4.9x).


Price to Earnings Ratio vs Industry

How does NEIMETH's PE Ratio compare vs other companies in the African Pharmaceuticals Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a6.9%
n/an/an/a

Price-To-Sales vs Industry: NEIMETH is expensive based on its Price-To-Sales Ratio (1x) compared to the African Pharmaceuticals industry average (1x)


Price to Sales Ratio vs Fair Ratio

What is NEIMETH's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

NEIMETH PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio1x
Fair PS Ration/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate NEIMETH's Price-To-Sales Fair Ratio for valuation analysis.


Share Price vs Fair Value

What is the Fair Price of NEIMETH when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: NEIMETH (NGN1.56) is trading above our estimate of fair value (NGN0.31)

Significantly Below Fair Value: NEIMETH is trading above our estimate of fair value.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.


Discover undervalued companies